Ted W Love
CIK 1188919 · President and CEO · last filed 2026-09-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
GBT price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
400 EAST JAMIE COURT, SUITE 101
SOUTH SAN FRANCISCO, CA 94080
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| JAZZ | Director | 2,389 | $234.93 | $561.2K | $0 | 3 | 2026-09-02 |
| GPCR | Director | — | $17.18 | — | $0 | 4 | 2026-06-18 |
| RPRX | Director | 58,393 | $67.70 | $3.95M | $0 | 7 | 2026-06-08 |
| GILD | Director | 5,484 | $167.06 | $916.1K | $0 | 4 | 2026-05-04 |
| Seagen Inc. (SGEN) Delisted | Director | 0 | $228.74 | $0 | $0 | 5 | 2023-12-15 |
| Global Blood Therapeutics, Inc. (GBT) Delisted | President and CEO | 0 | $68.49 | $0 | -$16.20M | 35 | 2022-10-06 |
| PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Director | 0 | — | — | $0 | 3 | 2020-07-02 |
| AMICUS THERAPEUTICS, INC. (FOLD) Delisted | Director | 131,000 | $14.49 | $1.90M | $0 | 11 | 2020-06-08 |
| Cascadian Therapeutics, Inc. (CASC) Delisted | Director | 37,394 | — | — | $97.5K | 5 | 2017-09-26 |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | Director | 13,005 | — | — | $0 | 4 | 2015-09-28 |
| HUMANIGEN, INC (KBIO) Delisted | Director | — | — | — | $0 | 2 | 2015-07-14 |
| MSTX | Director | — | $5.12 | — | $0 | 1 | 2013-06-21 |
| SANTARUS INC (SNTS) Delisted | Director | 335,500 | — | — | $2.01M | 11 | 2013-06-12 |
| Savara Inc (ANX) Delisted | Director | — | — | — | $0 | 1 | 2012-09-07 |
| ONYX PHARMACEUTICALS INC (ONXX) Delisted | EVP, R&D and Tech. Operations | 77,756 | — | — | -$387.7K | 6 | 2012-07-27 |
| AFFYMAX INC (AFFY) Delisted | Director | — | — | — | $0 | 6 | 2012-06-18 |
| Oruka Therapeutics, Inc. (ABIO) Delisted | Director | — | $28.80 | — | $0 | 2 | 2010-02-09 |
Holdings By Holder
| Symbol | Holder | Shares | Share of Total | Reported |
|---|---|---|---|---|
| GBT | Direct | 0 | — | 2022-10-06 |
| By Daughter | 0 | — | 2022-10-06 | |
| By Trust 2 | 0 | — | 2022-10-06 | |
| By Trust 1 | 0 | — | 2022-10-06 | |
| By Trust 3 | 0 | — | 2022-10-06 | |
| Total | 0 |
Recent Filings · Page 6 of 12
116 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-04-10 | Global Blood Therapeutics, Inc. (GBT) Delisted | Mixed | +18,225 | -$994.1K | EDGAR |
| 2019-02-05 | Global Blood Therapeutics, Inc. (GBT) Delisted | Mixed | +13,999 | -$378.5K | EDGAR |
| 2018-08-03 | Global Blood Therapeutics, Inc. (GBT) Delisted | Mixed | +10,996 | -$466.7K | EDGAR |
| 2018-07-17 | Global Blood Therapeutics, Inc. (GBT) Delisted | Exer (M) | +12,194 | $200.0K | EDGAR |
| 2018-06-11 | AMICUS THERAPEUTICS, INC. (FOLD) Delisted | Grant (A) | +3,081 | $0 | EDGAR |
| 2018-03-13 | — | Mixed | −37,394 | $0 | |
| 2018-02-16 | Global Blood Therapeutics, Inc. (GBT) Delisted | Mixed | +17,647 | -$1.08M | EDGAR |
| 2018-02-02 | Global Blood Therapeutics, Inc. (GBT) Delisted | Mixed | +23,729 | -$1.36M | EDGAR |
| 2018-01-26 | Global Blood Therapeutics, Inc. (GBT) Delisted | Mixed | +17,646 | -$1.01M | EDGAR |
| 2018-01-18 | Global Blood Therapeutics, Inc. (GBT) Delisted | Mixed | +17,917 | -$890.0K | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).